A study conducted by the Norwegian government compared Johnson & Johnson’s Remicade (infliximab) to Celltrion’s approved biosimilar Remsima.  The “NOR-SWITCH” study, which cost $2.5 million, was a 52-week Phase IV study that began in October 2014.  The results were presented on Tuesday during the United European Gastroenterology Week in Vienna, Austria.

The study concluded that “the switch” from Remicade to Remsima “was not inferior to continued treatment” with Remicade.

BioPharma Reporter has more details.